![]() Since then, about half a dozen projects worth at least $3 billion have been announced by companies including Lonza(LONN.S), Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm Corp, and Germany’s Vetter.Īnd with Lilly preparing to launch Mounjaro and Novo struggling to meet demand even as it rolls Wegovy out in more markets, the pace is accelerating.Īnother Novo partner, Thermo Fisher (TMO.N) is converting facilities used to fill COVID-19 vaccine syringes to handle pens for obesity and diabetes medicines, CEO Marc Casper told a Morgan Stanley health conference last month. The race for business among contract development and manufacturing organisations (CDMOs) began last year. The US company already does Wegovy fill-finish work. WuXi Biologics (2269.HK) CEO Chris Chen told Reuters his company is talking to clients about using pre-filled syringe capacity it is installing at a German factory it bought in 2020.ĭescribing interest as “pretty high”, he said he wants to buy more factories in Europe to serve GLP-1 customers, but did not give details.Ĭatalent is building “significant” pre-filled syringe capacity at factories in Anagni, Italy and Bloomington, Indiana, in the United States, said Cornell Stamoran, its vice president of corporate strategy and government affairs. The weekly weight-loss injections belong to a class of drugs known as GLP-1 agonists, which analysts estimate could be worth as much as $100 billion within a decade, including oral treatments now being developed by Pfizer (PFE.N) and others. Sales of Wegovy, the first of a new generation of obesity treatments which mimic the body’s appetite-suppressing hormones, have soared since its launch in the United States in June 2021.Įli Lilly’s (LLY.N) Mounjaro is expected to be approved for weight-loss in the United States this year.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |